Lilly del Caribe, Inc.

To evaluate the safety, tolerability and PK/PD characteristics of LY3502970 after multiple QD oral administration in Chinese obese or overweight subjects with weight-related comorbidities

The primary objective is to determine whether abemaciclib, an oral selective CDK4&6 inhibitor, can slow disease progression when added to abiraterone and prednisone. The study duration is approximately 60 months.

To compare the efficacy and safety of a fixed-duration course of venetoclax and rituximab with or without portpbitinib (LOXO-305) in patients with CLL/SLL who have received at least one prior line of therapy, which may have included a covalent BTK inhibitor (patients who have received and have not received prior BTK inhibitors will be enrolled).